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Background: The Epstein-Barr virus (EBV) is a causal agent in a number of malignancies in humans including
hematopoietic tumors and non-hematopoietic tumors. Burkitt’s lymphoma cell lines containing the Epstein-Barr
virus have been shown to form tumors in nude mice while clonal derivatives of such cell lines in which the viral
genome has been lost do not (JID 177: 1194-1201, 1998; JV 72: 9150-9156, 1998; JV 68: 6069-6073, 1994). The
re-introduction of EBV into these EBV negative BLs reconstitutes the tumor phenotype. Thus, EBV-induced cellular
genes play critical role in EBV-related tumors.
Methods and results: In an attempt to identify cellular genes regulated by EBV that may contribute to its
tumorigenic properties, we have enforced genome loss in the Burkitt’s lymphoma (BL) line, MutuI, by introducing a
dominant negative form of the episomal replication factor, EBNA1 and carried out gene array analysis. One of the
genes identified by this analysis is PLAC1, a gene originally identified as being expressed exclusively in placental
tissue. Real time RT-PCR analysis verified higher expression in EBV positive vs. EBV negative Mutu clones. Analysis of
a panel of RNAs from 20 normal tissues demonstrated the highest level of expression in placenta but significant
expression was also observed in testis and brain cerebellum. PLAC1 expression was also observed in non-BL tumor
cell lines derived from breast, ovary, and prostate. Lastly, expression of PLAC1 was found to be higher in some
primary breast tumors compared to normal adjacent tissues.
Conclusion: This data suggests that the EBV-induced PLAC1 is a member of the cancer/testis group of tumor
antigens.
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Placental specific gene 1 (Plac1) is a member of a family of
genes that have been identified as showing predominantly
placenta specific gene expression [1-5] with expression
being restricted to cells of trophoblastic lineage in the
mouse and human [1,2]. Trophoblasts play numerous
key roles in fetal development determined, in part, by
differentiating along distinct pathways. These include
the controlled invasion of extravillus trophoblasts into
maternal uterine tissue resulting in placental attachment
and regulatory interactions with the uterine vasculature.* Correspondence: qyin@tulane.edu
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unless otherwise stated.Additionally, multinucleated syncytiotrophoblasts are
metabolically active cells that are in direct contact with
the maternal circulation. They are responsible for many of
the functions essential to pregnancy maintenance, i.e.
nutrient and oxygen transport to the fetus, hormone
production and secretion, and elimination of fetal waste
products. As a support mechanism for these latter
functions, trophoblasts specifically promote angiogenesis
in part through the production of human chorionic
gonadotropin (hCG) and vascular endothelial growth
factor (VEGF) [6,7]. Lastly, the placenta also contributes
to immune tolerance necessary for effective placentation
and pregnancy maintenance.
The PLAC1 gene is located on the X chromosome
(Xq26.3) near the hypoxanthine-guanine phosphoribosyl
transferase (HPRT) gene [1]. PLAC1 is a 212 amino acidtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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brane domain and a cleavable signal peptide of 23 amino
acids (with a cleavage site following amino acid 23 [1]).
PLAC1 has homology to the zona pellucida 3 protein
(ZP3), a sperm binding glycoprotein which confers species
specificity during fertilization [1], and has a “zona pellucida
sperm-binding protein signature” between amino acids 89
and 106. Analysis of RNAs from a panel of normal tissues
showed predominantly placental expression. While little is
known regarding the function of PLAC1, lower circulating
levels of PLAC1 mRNA in maternal serum have been
shown to be associated with vaginal bleeding and
threatened abortion prior to week 20 suggesting a key
role for PLAC1 in trophoblast function [8]. Recently,
PLAC1 is recognized as an essential factor for normal
placental and embryonic development in mutant mouse
model [9].
The identification of tumor specific antigens for the
development of possible immunological cancer vaccines
has been of significant interest. The accumulated identifi-
cation of tumor specific antigens led to the recognition
of a wide array of genes of diverse function but sharing
a number of unique characteristics [10] including
expression in normal tissue being restricted to testis
(and often placenta), expression in a number of cancers,
association with tumor grade, and immunogenicity in
cancer patients [10]. In addition, many of these genes have
been found to be localized on the X chromosome. Based
on these common characteristics of genes with otherwise
diverse functions led to their being classified together and
referred to as “cancer/testis antigens (CT antigens)” [10].
Due to its localization on the surface of cancer cells,
PLAC1 provides accessibility to antibodies make them
attractive candidates for targeted immunotherapeutic
approaches for breast cancer and other tumor types [11].
The Epstein-Barr virus (EBV) is a causal agent in a num-
ber of malignancies in humans including nasopharyngeal
carcinoma, the endemic form of Burkitt’s lymphoma
(BL), Hodgkin’s disease, and a small percentage of
gastric carcinomas [12,13]. EBV is especially problematic
in immuno-compromised individuals and despite the
utilization of highly active retroviral therapy (HAART) to
treat AIDs patients, the incidence of EBV associated
non-Hodgkin’s lymphomas have increased [14,15].
In most tumors, EBV exists as an autonomously replicat-
ing episome. Episomal replication and segregation during
mitosis is facilitated in part by the EBV encoded nuclear
antigen, EBNA1 (Epstein-Barr virus nuclear antigen 1)
[16,17]. Previous studies have shown that either long term
culture, clonal selection, or treatment with hydroxyurea
can lead to the loss of EBV episomes in EBV positive
Burkitt’s lymphoma cell lines [18-20]. While these
EBV negative derivatives proliferate in tissue culture,
the parental BLs form colonies in soft agar and formtumors in nude mice, but the EBV negative derivatives do
not. Further, the re-introduction of EBV into these EBV
negative BLs reconstitutes the tumor phenotype. In an
effort to identify cellular genes regulated by EBV that may
contribute to the malignant phenotype, we enforced EBV
genome loss in the EBV positive BL line, MutuI, and
carried out gene array analysis of the resulting EBV
negative clones vs. the EBV positive progenitor cells.
Here we report that one of the genes identified in
this analysis is PLAC1. We also show that this gene
is expressed in testis and that it is expressed in other
tumors not associated with EBV. Based on its expression
profile and its localization to the X chromosome, we
propose that PLAC1 is a candidate CT antigen.
Results
To facilitate genome loss of EBV genomes in the BL line,
MutuI, a dominant negative form of the EBV episomal
replication/maintenance factor, EBNA1, was generated
as depicted in Figure 1a. An HA epitope tag and the
nuclear localization signal from the SV40 T antigen were
fused in frame to track expression and enforce nuclear
localization of the resulting protein, respectively. The
resulting gene cassette, EBNA1dn, was introduced into
two retroviral vectors, pMSCV-neo and pMSCV-puro
and introduced into MutuI cells on successive infections
with a 2 day interval between infections (Figure 1b).
pMSCV-neo-EBNA1dn and pMSCV-puro-EBNA1dn
infected cells and control infected cells (infected with
pMSCV-neo and pMSCV-puro) were selected for 10 days
following which a portion of cells were frozen in liquid
nitrogen and a portion were plated on 96 well plates for
cloning. In some cases, the frozen bulk cultures were
thawed and RNA was generated within 10 days for
analysis. Notably, only limited cell death was observed
indicating that the infection efficiency was relatively
high and that there was not a strong selection against
expression of EBNA1dn during this interval. Analysis
of 8 EBNA1dn infected clones showed no detectable
EBNA1 expression (Figure 1c) whereas all control infected
cells showed EBNA1 expression. PCR analysis of DNA
isolated from clones using primers that amplify 4 different
loci of the EBV genome revealed a complete loss of EBV
in clones 2–8 and trace amounts in clone 1 (Figure 1c).
To identify EBV regulated genes, total RNA was isolated
from clone 2.5 (EBNA1dn) and Mutu Cntl Bulk cultures
and subjected to gene array analysis using an Affymetrix
U133A2.0 gene chip. In a separate experiment, RNA was
isolated from clone 2.7 (EBNA1dn) and again compared
to freshly prepared total RNA from Mutu Cntl bulk cells.
One gene identified as being expressed at a lower level in
both EBNA1dn clones compared to the Cntl bulk cultures
was PLAC1. Two sets of PCR primers which amplify the
splice variants of PLAC1 were designed and used to
Figure 1 Generation of EBV negative derivatives of MutuI cells. a) Schematic representation of wild type and dominant negative forms of
EBNA1. b) Scheme for infection and selection of retrovirally infected MutuI cells. c) Analysis of infected clones for the presence of EBV. Top panel
shows Western blot analysis of EBNA1, actin and EBNA1dn. Antibodies used are described in materials and methods section. Lower panels show
PCR results analyzing the presence of EBV DNA in clones. Primers were generated which amplify regions within the indicated BamHI EBV
genomic fragments.
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cultures (Figure 2a). Expression of PLAC1 in Mutu
E1dn bulk cultures and Mutu Cntl bulk cultures were
first tested. Notably real time PCR analysis of EBV
genomes showed approximately 15 fold lower number of
EBV genomes in Mutu E1dn Bulk cultures compared toMutu Cntl Bulk cultures (data not shown). Real time
RT-PCR analysis showed approximately 6.5 fold lower
expression of PLAC1 in the Mutu E1dn bulk cultures
compared to Mutu Cntl bulk cultures (Figure 2b, left
panel). In contrast, no difference in PLAC1 expression
was observed in an EBV negative Burkitt’s lymphoma
Figure 2 Expression of PLAC1 in EBV positive vs. EBV negative MutuI cells. a) Schematic representation of two splicing variants for PLAC1
and position of PCR primers used for real time RT-PCR reactions. Primers are designed to span introns to avoid any potential amplification of trace
amounts of genomic DNA in RNA preparations. Gels show the amplified products from MutuI cells after 40 cycles. b) Real time RT-PCR analysis of
RNA derived from Mutu E1dn bulk vs Mutu Cntl bulk cultures and EBNA1dn infected DG75 (EBV negative) BL cell line. c) Real time RT-PCR analysis
of E1dn (EBV negative) and control (EBV positive) clones using primer set 1. d) Real time RT-PCR analysis of E1dn (EBV negative) and control
(EBV positive) cells using primer set 2.
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puro-E1dn (Figure 2b, right panel). Analysis of PLAC1
expression in control infected Mutu clones and EBNA1dn
infected Mutu clones (which are devoid of EBV genomes)
showed a more pronounced difference in PLAC1 expres-
sion using either primer set 1 or primer set 2 (Figure 2c
and 2d). These results indicate that EBV is required for
high level expression of PLAC1.
Previous studies had shown that expression of PLAC1
in normal tissues is restricted to placenta [1,2] by
Northern blot analysis. We assessed a panel of RNA
isolated from 20 primary tissues using a more sensitive
technique (quantitative RT-PCR) to more thoroughly
address this issue. As shown in Figure 3, little or no
expression was observed in most of the tissues testedwhile robust expression was observed in RNA isolated
from placenta. Nevertheless, this analysis also revealed
expression in RNA isolated from testis and brain cerebel-
lum. Analysis of PLAC1 expression in selected primary
tumor tissues revealed low expression in individual lung
and colon tumors but considerably higher expression in a
breast tumor (Figure 3).
We next analyzed a panel of EBV infected non-tumor
lymphomblastoid cell lines, EBV infected BLs, as well as
cell lines derived from several different tumor types. As
shown in Figure 4, the expression level of PLAC1 was
significantly higher in four EBV positive Burkitt’s
lymphoma cell lines compared with the EBV negative
Burkitt’s lymphoma cell line, DG75. Some expression
was observed in two EBV positive lymphoblastoid cell
Figure 3 Analysis of PLAC1 expression in RNAs derived from
primary tissues and selected primary tumor tissues. Real time
RT-PCR was carried out using primer set 1. Fold difference is the
expression level relative to the average of expression in tissues with
low expression (i.e. all normal tissues except testis, placenta and
brain cerebellum).
Figure 4 Analysis of PLAC1 expression in various tumor and
non-tumor derived cell lines. DG75 is an EBV negative Burkitt’s
lymphoma cell line. IB4 and JY are EBV immortalized lymphoblastoid
cell lines and P3HR1, Rael, Akata, and MutuI are EBV positive Burkitt’s
lymphoma cell lines. MDA-MB-231 and MDA-MB-361 are breast
cancer derived cell lines, CaoV3 and BG1 are ovarian cancer derived
cell lines, LNCAP and PC3 are prostate cancer derived cell lines. Fold
difference represents the level of PLAC1 or GAPDH expression in the
indicated cell lines vs. the average expression of normal tissues
from Figure 3).
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the two ovarian tumor cell lines tested (Figure 4). The
highest expression was observed in the highly aggressive
and invasive breast cancer cell line, MDA-MB-231 [21],
whereas relatively lower expression was observed in the
less aggressive breast tumor line, MD-MB-361. Expression
was also observed in two prostate cancer cell lines tested
while significantly higher expression was observed in the
more aggressive androgen receptor negative line, PC3.
These results indicate that PLAC1 is expressed in several
EBV associated BL lines as well as in several tumor cell
lines not associated with EBV.We next assessed PLAC1 expression in matched
tissues from breast cancer patients comparing expression
in the tumor mass relative to adjacent non-tumor tissue.
As shown in Figure 5, significantly higher expression was
observed in tumor vs. normal breast tissue in patients B
and E. In contrast, little difference in the expression of the
housekeeping genes, mATPsy6 [22] and RNASE T2 was
observed. It will be interesting to determine the status of
Figure 5 Comparison of PLAC1 expression in matched primary
tissue from breast cancer patients. RNAs from tumor or adjacent
normal tissue were analyzed by real time RT-PCR using primer set 1,
primer set 2 and the two control genes, mATPsy6 and RNASE T2.
Values represent expression in tumor RNA vs. corresponding normal
adjacent tissue. GAPDH was excluded as a control because previous
studies have shown a correlation between GAPDH expression and
breast cancer aggressiveness [23,24].
Wang et al. Virology Journal 2014, 11:107 Page 6 of 10
http://www.virologyj.com/content/11/1/107EBV in these primary breast tumors though the matched
DNA is not available for these samples.
Discussion
We show here that like previous studies [1,2], PLAC1
expression is highly limited in normal tissues. Nevertheless,
using real time RT-PCR, we have observed that PLAC1
expression can be detected in testis and cerebellum.
PLAC1’s higher level of expression in EBV positive MutuI
cells relative to EBV negative Mutu cells led us to test the
expression PLAC1 in a panel of tumor cell lines. This
analysis revealed that PLAC1 is highly expressed in
several Burkitt’s lymphoma cell lines as well as tumor
cell lines derived from a number of other cancers.
Using RNAs isolated from primary matched tumor
and normal tissues, we further determined a higher level
of PLAC1 expression is some tumor samples. This raises
the possibility that PLAC1 may be a member of the
expanding group of CT antigens.
The first CT antigens described were identified using
screens to identify antigenic proteins in cancer patients
that are specifically expressed in tumor cells with the
hopes of identifying targets for immunotherapy. Another
common but not exclusive feature of CT antigens is
their inducibility by hypomethylating agents and/or
histone deacetylase inhibitors. At this time we have not
tested this issue but it is notable that the promoter for
PLAC1 is devoid of CpG dinucleotides and thereforemay not be subjected to CpG methylation dependent
silencing. Nevertheless, it does seem likely that PLAC1
might be silenced through some epigenetic imprinting
mechanism involving histone deacetylases.
There are several functions that both the placenta and
tumors provide which are required for and/or enhance the
survival of the fetus and the tumor. The placenta is the key
organ responsible for the exchange of nutrients and waste
materials to and from the fetus. While these activities are
mediated by specific transport mechanisms, this process is
enhanced through the synthesis of angiogenesis promoting
factors such as vascular endothelial growth factor
(VEGF) and human chorionic gonadotropin (hCG) by
the trophoblast [6,7]. Similarly, hypoxic conditions in
tumors can promote the synthesis of angiogenic factors
such as VEGF, which in turn leads to angiogenesis.
Another key function of the placenta is to protect the
fetus from immuno-surveillance by the mother. Both the
fetus and the placenta are of fetal origin and therefore are
immunologically distinct from the mother. The placenta
utilizes multiple mechanisms to prevent immunological
targeting by the mother’s immune system including the
down regulation of major histocompatibility complex
(MHC) II proteins [25]. Similarly, tumors have been
shown to down regulate MHC proteins [26]. Tumors can
also secrete cytokines that enhance the recruitment of
tolerance inducing immune cells [27] and this also appears
to be a key mechanism utilized by the placenta to
prevent fetal targeting [28]. Another commonality
between the synciotrophoblasts and invasive tumors is
their production of metalloproteinases (MMPs) which
serve to promote the invasive properties of the tumor
and of the synciotrophoblasts [4].
Other studies have previously found molecular links
between trophoblasts and malignant cells. Acevedo et al.
discovered that 28 out of 28 randomly selected cancer
cell lines express a membrane form of hCG [29]. In
another study, Goshen et al. found that a specific splice
variant of CD44 which is found in metastasizing human
malignancies and is thought to play an important role in
metastatic spread, is also expressed in invasive extravillous
trophoblasts [30]. These authors propose that this splice
variant may similarly play a role in trophoblast invasion.
Interestingly, a previous study also found that another
Epstein-Barr virus induced gene, EBI3 (Epstein-Barr
virus inducible 3) is expressed at high levels in the
syncytiotrophoblasts [31,32]. Together, there is accumulat-
ing data indicating that there are not only numerous
functional similarities between tumors and the placenta
but that there are also some similarities in the mechanisms,
which mediate these common functions. The findings that
PLAC1 is expressed in both tumors and in trophoblasts
provide an additional molecular link between the two.
While there is a limited knowledge regarding the function
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that it is crucial for fetal development [8] and for
embryonic development [9]. Knockdown of PLAC1 in
breast cancer cells not only blocks cell cycle and
proliferation, but also impairs cell motility, migration and
invasion probably through inhibiting the cyclin D1
and the phosphorylation of AKT kinase [11]. It will
be interesting to ultimately determine how PLAC1
expression functions and whether it similarly promotes
one or more key survival functions in tumors.
The number of latency associated genes expressed in
EBV associated tissues varies according to the tumor
and cell type. Typically, primary Burkitt’s lymphomas
express a limited set of viral genes: EBNA1, two small
non-coding Pol III derived transcripts referred to as
EBER1 and EBER2, and a set of alternatively spliced
products derived from the BamHI A region of the EBV
genome (latency type I genes) [17]. In EBV immortalized
non-tumor lymphoblastoid cell lines, a larger group of
EBV encoded genes are expressed (latency type III
genes) which are important for maintaining the growth
phenotype of the infected cell [17]. In this case, the EBV
encoded genes, EBNA1, EBERs, BamHI transcripts, plus
EBNA2, EBNA-LP, EBNA3A, EBNA3B, EBNA3C and
the latent membrane proteins, LMP1 and LMP2 are
expressed. Many of the EBV genes unique to the type III
program (relative to the type I program) are each essen-
tial for providing the growth phenotype to lymphoblas-
toid cell lines. In line with this, the growth phenotype of
Burkitt’s lymphoma cells is probably dictated principally
through genetic alterations such as the c-Myc transloca-
tion to the immunoglobulin locus [33], the defining
translocation of Burkitt’s lymphomas. Accordingly, the
EBV genome can be eradicated in Burkitt’s lymphoma
cell lines without abrogating the proliferative capacity of
the derived cells [18-20]. Nevertheless, it is clear that
type I gene expression contributes to the tumor pheno-
type of Burkitt’s lymphoma cells since the loss of EBV in
these cells results in cells that cannot form colonies in
soft agar and cannot form tumors in SCID mice. This
indicates that the type I genes likely play key roles in
tumorigenesis other than simply promoting cell growth
and it is possible that type I EBV gene expression con-
tributes some of the characteristics that are common to
tumors and placenta outlined above. It is notable that of
the B-cell lines tested, the highest expression of PLAC1
was observed in the type I BL lines (note: although
P3HR1 is a Burkitt’s lymphoma derived cell line, these
cells display a group II/III gene expression pattern).
This indicates that induction of PLAC1 by EBV is
likely facilitated principally by the type I gene expression
pattern. It will be interesting to determine whether expres-
sion of PLAC1 might contribute to one or more of the
tumorigenic properties of EBV.Conclusions
Enforced genome loss of EBV and carried out gene array
and real time RT-PCR analysis, we identify that EBV
induces PLAC1 gene. Based on its expression profile
and its localization to the X chromosome, we propose
that PLAC1 is a candidate CT antigen.
Materials and methods
Cell culture
All B-cell lines, LNCAP and PC3 cell lines were propagated
in RPMI supplemented with 10% fetal bovine serum
albumin, penicillin, streptomycin, and glutamine. Hela,
293, MDA-MB-231, MDA-MD-361, CaoV3, and BG1
cells were propagated in Dulbecco’s Modified Eagles
Medium (DMEM; Life Technologies) supplemented with
10% fetal bovine serum albumin, penicillin, streptomycin,
and glutamine. Cells were cultured at 37°C in a humidified
5% CO2-containing atmosphere.
Retroviral infections
Transient transfection experiments were performed by
using a modified version of the calcium phosphate
precipitation procedure (a detailed protocol is available at
flemingtonlab.com). Briefly, 106 cells were plated onto
100-mm-diameter tissue culture dishes. The following
day, the medium was replaced with 8 ml of fresh
supplemented DMEM; 4 h later, DNA precipitates were
generated by mixing 0.5 ml of 1x HEPES-buffered saline
(0.5% HEPES, 0.8% NaCl, 0.1% dextrose, 0.01% anhydrous
Na2HPO4, 0.37% KCl [pH 7.10]) with a total of 30 μg of
plasmid DNA (10 μg retroviral vector plus 10 μg VSV-G
expression vector, plus 10 μg pVPACK dGI packaging
vector). A total of 30 μl of 2.5 M CaCl2 was added, and
samples were mixed immediately. Precipitates were allowed
to form at room temperature for 20 min before being
added drop wise to cells. Cells were incubated at 37°C with
5% CO2 for 16 h before the medium was replaced with
10 ml of fresh DMEM (plus 10% FBS).
24 hrs later, viral supernatants were collected and sub-
jected to two rounds of centrifugation to get rid of floating
293 cells. Infections were carried out in 6 well plates with
1 ml virus plus 106 MutuI or DG75 cells suspended in
1 ml DME (+10% fetal bovine serum). Polybrene was
added to a final concentration of 8 ug/ml and the mixture
was mixed by gently rocking. Cells were spun in 6 well
plates at 1000 g for 1 hr followed by 4 hr incubation in a
tissue culture incubator. Cells were then collected, spun
down and resuspended in 2 ml RPMI (+10% fetal bovine
serum, + penicillin, streptomycin, and glutamine) per well.
Cells were cultured for 2 days prior to antibiotic selection.
Western blot analysis
After a single 1× PBS wash, cells were immediately
suspended in 300 μl of sodium dodecyl sulfate
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(125 mM Tris [pH 6.80], 10% glycerol, 2% SDS, 5%
2-mercaptoethanol, 0.05% bromphenol blue) and
boiled for 20 min to shear the genomic DNA. Whole-cell
extracts were measured with the Bio-Rad protein assay kit
according to the manufacturer's instructions. An equal
weight of cell lysates was subjected to SDS-polyacrylamide
gel electrophoresis and transferred to nitrocellulose
membranes. The blots were blocked for 30 min in Tris-
buffered saline containing 5% low-fat powdered milk and
1% FBS and then incubated with the primary antibody
(in blocking buffer) overnight at 4°C. The blots were
washed three times with 1× TBST (140 mM NaCl,
3 mM KCl, 25 mM Tris–HCl [pH 7.4], 0.1% Tween 20)
(each wash was carried out for approximately 10 min). The
blots were then incubated with horseradish peroxidase-
conjugated secondary antibody (Bio-Rad) in blocking
buffer for 1 h at room temperature. Blots were washed
as described above and analyzed with an enhanced
chemiluminescence detection system (Perkin-Elmer)
according to the manufacturer's recommendations, and
filters were exposed to Fuji Super RX film. The following
antibodies were used for Western blot analysis:
EBNA1 (Advanced Biotechonologies Incorporated,
CAT# 13-156-100, 1:1000 dilution), HA.11 (Boehringer
Mannheim, Cat# 1 867 431, 1:1000 dilution), Actin (Sigma,
Cat# A 4700, 1:1000 dilution).
Real time RT-PCR
RNAs from cells were prepared using a RNeasy® Mini
kit from Qiagen (Cat# 74104) according to vendor’s
protocol. Normal tissue RNAs were purchased from
BD Biosciences (Cat# 636643). Individual RNAs from
primary lung (Cat#64013-1), colon (Cat#64014-1),
and breast (Cat#64015-1) tumors were purchases
from BD Biosciences. qPCR human matched pair total
RNA panel was purchased from BD Biosciences (Cat#
636691).
cDNA synthesis was carried out using Superscript™ III
first-strand synthesis system for RT-PCR (Invitrogen,
Cat#. 18080–051). 2 ug of RNA were used for first strand
synthesis and then diluted to a final volume of 200 ul.
Real Time PCR was carried out using 5 ul of diluted
cDNA for each 20 ul reaction. Analysis was carried out on
a BioRad iCycler using BioRad iQ™ SYBR Green supermix
(CAT#170-8882) with the following conditions: 95°C 3'
then 40 cycles of 95°C 30", 60°C 30", and 72C 30”. Primer
sequences for real time PCR were the following: PLAC1;
PLAC1-PS1-sense, 5' - TTCACCAGTGAGCACAAAGC -
3' and PLAC1-PS1-antisense, 5' - CCAGTCTATGGAG
CACAGCA - 3', PLAC1-PS2-sense 5' -GGGCAAATACA
GACACAGCA -3' and PLAC1-PS2-antisense 5' -CCAGT
CTATGGAGCACAGCA -3', GAPDH; GAPDH-sense, 5' -
GCCAAGGTCATCCATGACAACTTTGG - 3' and GAPDH-antisense, 5' - GCCTGCTTCACCACCTTCTTGAT
GTC - 3', mATPsy6 [22]; mATGsy6-sense, 5’-GGGCGC
AGTGATTATAGGCTT-3’ and mATPsy6-antisense, 5’-
GGTGTAGGTGTGCCTTGTGGT-3’, RNASE T2; RNASE
T2-sense, 5' -TGGGGATAAAACCATCCATC -3' and RNA
SE T2-antisense, 5'-AGCTGCTGGTCTTGCTTAGT-3'.
For analysis of EBV DNA in Mutu Clones, genomic
DNA was isolated as describe at flemingtonlab.com.
PCR analysis was carried out essentially as described
above for RT-PCR analysis except that the following
conditions were used: 95°C 3' then 40 cycles of 95°C 30",
55°C 30", and 72C 30”. The following primers were used
to amplify different parts of the EBV genome: BamHI R
primers (Rp); R-left, 5'-TAGTTAATGCCCCAGCCA
GA-3', R-right, 5'-CTTTAAAAAGGCCGGCTGAC-3',
BamHI M primers (BMRF1p) [34]; M-right, 5'-ACCTA
CATGACTAGCATCAAGCAA-3', and M-left, 5'-GGCC
TCCATAGTTTACAGACAGAA-3', BamHI Q primers
(Qp); Q-left, 5'-AAATTGGGTGACCACTGAGG-3' and
Q-right, 5'-CATACACCGTGCGAAAAGAA-3', BamHI K
primers (EBNA1); K-left, 5'-AAGGAGGGTGGTTTGGA
AAG-3' and K-right, 5'-TGGAATAGCAAGGCCAATTCC-3'.
Plasmid construction
To generate dominant negative forms of EBNA1, full
length EBNA1 was first excised from the plasmid,
pCEP4, with ClaI and SacII. Since the SacII digestion
cleaves the last few carboxy-terminal amino acids
from the EBNA1 reading frame, two adaptors were
synthesized which together encode the terminal amino





GGAGTGA-3’, Adaptor 2-antisense; 5’-GATCTCACTCC
TGCCCTTCCTCACCCTCATCTC-3’). The ClaI/SacII
EBNA1 fragment was ligated to EcoRI and BglII cut
pMSCV-neo vector in the presence of Adaptor 1 plus
Adaptor 2, plus an EcoRI/ClaI adaptor (from eZclone
Systems). Ligations were carried out in the presence of
1 ul T4 polynucleotide Kinase to phosphorylate adaptors
during ligation reaction. This construction led to the
generation of pMSCV-neo-EBNA1wt. pMSCV-neo-E1dn
was generated from this plasmid by digesting pMSCV-
neo-EBNA1wt with EcoRI and ApaI to excise the amino
terminal EBNA1 sequences. The resulting vector plus
carboxyl terminal EBNA1 sequences were then ligated to
three adaptors which when linked together contain a
translation initiation sequence, an HA epitope tag, the
SV40 nuclear localization signal plus an EcoRI over-
hang at the 5’ end and an ApaI overhang at the 3’
end (DN adaptor 1-sense; 5’-AATTCTGCTGAAGAT
GATGGCCTATCCTTATG-3’, DN adaptor 1-antisense;
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ATGTGCCTGACTATGCCGCCCCAAAGAAA-3’, DN
adaptor 2-antisense; 5’-CATAGTCAGGCACATCA
TAAGGATAGGC-3’, DN adaptor 3-sense; 5’-AAGC
GAAAGGTGGCCGGCC-‘3, DN adaptor 3-antisense;
5’-GGCCACCTTTCGCTTTTTCTTTGGGGCGG-3’).
Ligations were carried out in a standard ligation reaction
except that 1 ul of T4 polynucleotide kinase was
added to phosphorylate adaptors during ligation reac-
tion. This strategy generated pMSCV-neo-EBNA1dn.
pMSCV-puro-EBNA1dn was derived from this plasmid
by simply excising the HA/nls/EBNA1dn cassette
from pMSCV-neo-EBNA1dn and transferring to pMSCV-
puro using appropriate standard cloning adaptors. All
constructs were verified by sequence analysis.
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